cocaine which, as Gasser (1934) showed, paralyses the small slowly conducting fibres first and the large fibres last; pain and the vasomotor nerves are paralysed early, touch later. A somewhat intermediate position is occupied by cooling, which picks out the cold, motor and vasomotor fibres early, touch second and pain and warmth last (Bickford, 1939) .
. These patterns of differential paralysis of nerves undoubtedly represent physicochemical differences in the nerve fibres themselves, and this irrespective of whether the differential paralysis is a manifestation of fibre size, or of their frequencies and patterns of impulses, which some believe to represent the way in which different modalities are conducted (for review see Sinclair, 1955) . I am not aware of any observations on diabetic neuropathy that are sufficiently searching to enable a conclusion to be drawn as to whether the loss of function corresponds closely to any of these three patterns or is different. HoweVer, the relatively early and severe lesions in postganglionic fibres seem quite unlike the pattern found in ischmmia; and of course there is no doubt that the postganglionic fibres are small and unmyelinated.
The chief interest of diabetic neuropathy to me lies in its meaning. All observers are agreed that there is a correlation between the nervous lesions, those of the retina so recently and admirably reviewed by Ashton (1959) , and the Kimmelstiel-Wilson lesion of the kidney. While it is probable that they represent three separate manifestations of one and the same biochemical fault, we may, for the purposes of this discussion, restrict our attention to the nervous lesioin. Woltman and Wilder (1929) believed that neither glycosuria nor acidosis played a direct part; nor did infection. They therefore considered the lesions were due to atherosclerosis affecting the blood supply of the nerve trunks. While Rundles (1945) noted that neuropathy was particularly prone to develop in patients whose diabetes was poorly controlled, 56% of his patients had never had coma, acidosis or ketosis so far as could be ascertained. Fagerberg (1959) has recently shown the frequency of deposits of PAS-staining material in the arteries of the sural nerve in diabetes, and again argues the case for ischmmia. However, two arguments make this improbable. In the first place, as Martin (1953b) showed, the blood supply to the affected limb is in many cases good. In the second place, as I have shown above, the pattern of loss of function is quite unlike that of ischaemia.
I would like, therefore, to suggest that the lesion of the peripheral nerves is one of the manifestations of the basic biochemical fault that underlies a certain type of diabetes. It is not impossible that this biochemical fault is the manifestation of a single gene, though the evidence is quite inconclusive. But it seems to me possible that if we could define more accurately the biochemical fault in diabetic neuropathy, we might obtain a new approach to the nature of at least one form of diabetes. London KNOWLEDGE of the biochemical changes that accompany different forms of peripheral neuropathy is still very limited. One biochemical lesion, however, that has been shown to exist in certain types of polyneuritis is a disorder of pyruvate metabolism, and because of these limitations in our knowledge, this communication is mainly concerned with pyruvate metabolism in diabetic neuropathy.
Pyruvate Metabolism in Diabetic Neuropathy
It must be made clear, however, at the outset that although the studies which we have carried out have provided results of interest to the wider problems of diabetes mellitus, they have not as yet produced any positive evidence on which we can build any theory to account for the development of diabetic neuropathy. They have, however, served to exclude certain possibilities, and suggest perhaps a re-directing of our thoughts, and it is for this latter reason that we have thought it worth while to describe them briefly here.
The clinical similarity that exists between certain cases of diabetic neuropathy and the polyneuritis associated with thiamine deficiency led, as is well known, to the suggestion that this peripheral neurological complication of diabetes might be the outcome of a co-existing deficiency of vitamin B1. In order to test this hypothesis Goodhart and Sinclair in 1940 estimated the level of thiamine in the blood, in the form of its pyrophosphate ester which can be regarded as the active derivative of thiamine, in 5 patients with diabetic neuropathy. In 4 out of the 5 patients they found normal levels. The 5th patient, in whom a low level was found, was also an alcoholic, which could of course account by itself for the decreased thiamine level.
Studies were also made, between 1940 and 1943, of the urinary excretion of thiamine before and after a test dose of the vitamin in diabetic patients, with and without signs of peripheral neuritis, and again in the vast majority of cases the values found were within the normal range (Robinson et al., 1940; Pollack et al., 1941; Needles, 1943) .
Despite these findings, however, several observers claimed that clinical improvement occurred in patients with diabetic neuropathy following the administration of the vitamin (Fein et al., 1940; Rudy and Epstein, 1945) , although other subsequent investigators found that even massive doses of thiamine given intramuscularly failed to produce any improvement Martin, 1953) .
There is therefore no clear or even adequate evidence to support the suggestion that diabetic neuropathy is in the main due to an accompanying thiamine deficiency.
It is, however, now known that the underlying biochemical lesion in thiamine deficiency, namely a block in the normal oxidative pathway of pyruvate metabolism inside the cells, can be produced by a variety of causes other than thiamine deficiency. Further, it is known that certain of these other causes can also manifest the block in pyruvate metabolism by bringing about the development of a peripheral neuritis closely resembling that due to a thiamine deficiency. For example, arsenical polyneuritis is now known to be associated with an inactivation of certain of the enzyme-coenzyme systems concerned in the oxidation of pyruvate, 8 this inactivation resulting from a chemical interaction between the arsenical compound and certain essential sulphhydryl groups in the enzyme system.
Lesions of this type, resulting in impairment of utilization of pyruvate should theoretically be capable of detection by measuring the blood pyruvate level after a loading dose of glucose which will in part be converted into pyruvate inside the cells of the body; if further metabolism of the pyruvate so formed is impaired, then abnormally high levels of blood pyruvate might be expected to occur.
For example, Joiner, McArdle and Thompson applied such a test in 1950 to a group of 40 cases of polyneuritis of different types, together with a group of 50 control subjects. They found that just over half of the patients with polyneuritis showed high blood pyruvate levels at either 60 or 90 minutes after the dose of glucose. By repeating the test after fourteen days of massive parenteral thiamine therapy they were able to show that only a small proportion of these patients showing high blood pyruvate levels had had their pyruvate metabolism restored to normal by the vitamin therapy. The remaining patients showing high pyruvate levels must therefore have had an impairment of pyruvate metabolism due to some other cause.
In view of the known abnormalities of carbohydrate metabolism in the diabetic patient it seemed therefore to be of particular interest to study the blood pyruvate levels in patients with diabetic neuropathy.
In the earlier series Joiner, McArdle and Thompson had included 4 patients with diabetic neuropathy, and had found that in each of them there was virtually no rise in the pyruvate level following the loading dose of glucose. This was in agreement with the finding of Bueding et al. (1942) and others, that diabetic subjects without neuropathy also show little or no rise in the blood pyruvate level following the administration of glucose.
This may be attributable to the fact that the diabetic subject is suffering from a relative insulin deficiency, so that the utilization of the loading dose of glucose will be impaired. The blood pyruvate level will only rise as a result of pyruvate entering the tissue fluids from the cells, and if, owing to insulin lack, the entry of the glucose into the cells is impaired, then only a small amount of pyruvate will be formed inside the cells from the loading dose. In other words, an insufficient amount of the loading dose may be entering the cells to yield sufficient pyruvate to show a rise in the blood level if any block in pyruvate metabolism were present.
If, however, a dose of insulin is given to the diabetic subject at the same time as the loading dose of glucose is taken, then, if that insulin is effective inside the body, it might be expected to increase the rate of glucose entry into the cells sufficiently to show an abnormal rise of blood pyruvate, should any block to pyruvate utilization exist. We therefore gave 7 units of insulin intravenously, together with the oral gl: cose, and were able to show that a proportion of diabetic subjects did then show a strikingly abnormal, high rise in the blood pyruvate level , (Butterfield and Thompson, 1957) ; for example, in a recent series we have shown that 18 out of a group of 53 diabetic subjects gave an abnormal rise in the pyruvate level after the administration of glucose and insulin (Butterfield et al., 1959) . The highest levels in general appear to be found in those patients who are poorly controlled. Martin (1953) had earlier studied 8 patients with diabetic neuritis using, not a loading dose of glucose, but an intravenous infusion of pyruvate. In this small series he was not able to find any evidence of abnormal pyruvate metabolism, although he himself appears to have found the results of this approach unsatisfactory on technical grounds.
Furthermore, although alloxan diabetes may present a different and possibly a more complex metabolic picture, there is certainly evidence that in this condition also pyruvate metabolism is defective. Thus, Pearson et al. (1949) have shown that cardiac and diaphragm muscle from alloxan-diabetic rats show a diminished ability to convert pyruvate to C02, and El Hawary and Thompson (1954) found a significant rise in the blood pyruvate level of alloxan-diabetic rats.
Because of the evidence that now exists of abnormal pyruvate metabolism in at any rate a proportion of diabetic subjects it was decided next to investigate whether there is any correlation between high pyruvate levels and the existence of neuropathy by measuring blood pyruvate levels during glucose-insulin tests.
We have therefore recently carried out these measurements in 18 diabetic patients showing involvement of the peripheral nervous system. These 18 patients comprised 4 groups:
(1) 12 patients with chronic peripheral neuritis, all showing signs of bilateral sensory and reflex changes, with or without weakness. Patients with absent ankle-jerks or impaired vibration sense without other signs were not included.
(2) 2 patients with acute peripheral neuritis, showing bilateral sensory and reflex changes without weakness; these patients were badly controlled and the symptoms improved rapidly with treatment.
(3) 2 patients with mononeuritis multiplex, the first with a right radial and left lateral popliteal palsy, and the other with a right ulnar and bilateral popliteal lesions.
(4) 2 patients with diabetic amyotrophy (Garland, 1955) .
In carrying out the tests, 50 grams of glucose was given by mouth, and 7 units of insulin injected intravenously. Blood was taken at zero time, in the fasting, rested state, and again at 60 minutes after the dose of glucose and insulin, the patient being kept at rest.
Pyruvate was estimated by the method of Friedemann and Haugen (1943) . In addition to pyruvic acid, this method will also estimate, to varying degrees, other keto acids including aceto-acetic acid. In studying diabetic patients in particular, it is therefore important to demonstrate that high pyruvate levels, as determined by the Friedemann and Haugen method, are in fact due to pyruvate and not to aceto-acetate. In a series of patients showing particularly high levels, or who were known to be liable to develop ketosis, we have therefore also estimated pyruvic acid by a specific method involving paper chromatographic separation of the pyruvic acid from the other keto acids present in the blood extract (McArdle, 1957) . Closely similar values were obtained by the two methods, particularly in the case of the rise in the level after administration of glucose. Table I shows the mean values obtained in a Taken as a group it will be seen that there is no evidence that the blood pyruvate levels are higher in the patients with neuropathy than in other diabetics. The fasting levels in the 2 groups are closely similar, although they are distinctly higher than the fasting level in normal subjects but both the 60-minute figure and the rise are actually lower in the patients with neuropathy than in those without neurological signs or symptoms.
6 of the 12 patients with chronic peripheral neuritis showed pyruvate levels above the expected normal range, the other 6 giving normal results. Both the patients with mononeuritis multiplex and both of the amyotrophic subjects gave normal results.
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On the other hand the 2 patients with acute peripheral neuritis showed high values. Despite this we hesitate to relate the onset of the neurological symptoms in these 2 cases to the observed defect of pyruvate metabolism, since both patients were badly controlled, with blood sugar levels of over 300 mg/100 ml, and it is in just -this type of patient that high pyruvate levels are to be expected even in the absence of neurological ,complications.
It would seem therefore that high blood pyruvate levels are found no more frequently in diabetics with neuropathy than in other types of diabetic patient. So that, just as there is little real evidence of any association with thiamine ,deficiency, we must also conclude that there is as yet no clear evidence for regarding diabetic neuropathy as due to any other type of impairment of pyruvate metabolism.
At the same time, we now know that many diabetics have a demonstrable abnormality of pyruvate metabolism, and it should perhaps be pointed out that the methods that we have been using, involving analysis on samples of venous blood from the forearm, are relatively crude for the investigation of chronic and perhaps only slight biochemical changes in nerve cells, and we may have to refine our techniques still more before we can with certainty exclude a defect in oxidative metabolism in nerve cells in diabetic neuropathy.
So far, however, we must admit that biochemical investigations into this condition have yielded little that is of positive help. Knowing, however, the extent to which nerve cells appear to depend on the metabolism of glucose for the provision of energy for their normal functioning, it is perhaps to be expected that signs of abnormal functioning in peripheral nerves might be found in a condition involving subnormal glucose utilization by the peripheral tissues, even though the oxidation of glucose by the central nervous system appears to be largely independent of insulin.
At present, however, we can do little more than theorize on the biochemical level as to why peripheral neuropathy should develop in some patients and not in others. Is it due, for example, to variations in the efficiency of the intracellular metabolism, at a level higher than pyruvate, of the subnormal amounts of glucose entering the cells, these variations being dependent perhaps on the levels of the necessary enzyme-coenzyme system?
The levels of these systems will depend on continued protein synthesis, which would appear to be deranged in diabetes mellitus, and which may be more deranged in some subjects than in others. These levels may again be influenced by the degree of accompanying vascular changes in the nerves.
Another possibility, bearing in mind the known abnormalities in lipid metabolism in diabetes, is that in the diabetic subject there may develop a defect in the synthesis of the relatively large amounts of those particular long-chain fatty acids that are present in the lipids of the nervous system. It is also possible that the raised blood sugar level may affect nervous excitability, since Feldberg (1944) has shown that concentrations of glucose of 0 2% or over inhibit the synthesis of acetylcholine by nerve tissue.
Finally, we must certainly not exclude the possibility that certain types of human diabetes may be associated with the presence of a circulating alloxan-like substance, derived perhaps from some derangement of purine metabolism. Since alloxan is a powerful SH inhibitor, and since it is known that SH inhibitors can produce neuropathies, the presence of an alloxan-like substance might account not only for ,-cell damage, but might also explain why in some patients neuritic symptoms develop at so early a stage in the disease, or may indeed be the presenting features.
All these, of course, are speculations, and it is clear that much more work, and on a much wider front, is needed to explore the complex metabolic abnormalities that certainly exist in this condition.
